Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early…
Vir Biotechnology, Inc. and GlaxoSmithKline plc announced an agreement with the U.K.-based AGILE initiative to evaluate VIR-7832 in patients with mild to moderate COVID-19 in a Phase…
Read More...
Read More...
